Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2005-0099 NCT00147225


2.		Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care				Active				18 and over				Other				2005-0146 NCT00299182


3.		Determination of Safe Dose of Romiplostim (Formerly AMG 531) in Subjects With MDS

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Active				18 and over				Pharmaceutical / Industry				20050159 NCT00303472


4.		Determination of Safe and Effective Dose of AMG 531 in Subjects With MDS Receiving Hypomethylating Agents

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				20050232 NCT00321711


5.		Dose/ Schedule Finding Trial of AMG 531 for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				18 and over				Pharmaceutical / Industry				20050154 NCT00413283


6.		A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				18 and over				Pharmaceutical / Industry				20060102 NCT00418665


7.		Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Active				18 to 90				Pharmaceutical / Industry				20060198 NCT00614523


8.		Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Supportive care				Active				18 and over				Pharmaceutical / Industry				20060197 NCT00472290

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute